PNV Stock Overview
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 2/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
PolyNovo Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$2.06 |
52 Week High | AU$2.52 |
52 Week Low | AU$1.10 |
Beta | 1.6 |
1 Month Change | -3.29% |
3 Month Change | 30.38% |
1 Year Change | 26.38% |
3 Year Change | -35.22% |
5 Year Change | 114.58% |
Change since IPO | 2,188.89% |
Recent News & Updates
Recent updates
Shareholder Returns
PNV | AU Medical Equipment | AU Market | |
---|---|---|---|
7D | -4.6% | -1.7% | -2.2% |
1Y | 26.4% | 14.6% | 4.5% |
Return vs Industry: PNV exceeded the Australian Medical Equipment industry which returned 14.6% over the past year.
Return vs Market: PNV exceeded the Australian Market which returned 4.5% over the past year.
Price Volatility
PNV volatility | |
---|---|
PNV Average Weekly Movement | 7.1% |
Medical Equipment Industry Average Movement | 10.2% |
Market Average Movement | 9.0% |
10% most volatile stocks in AU Market | 17.6% |
10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: PNV's share price has been volatile over the past 3 months.
Volatility Over Time: PNV's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 237 | Swami Raote | www.polynovo.com |
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product.
PolyNovo Limited Fundamentals Summary
PNV fundamental statistics | |
---|---|
Market cap | AU$1.42b |
Earnings (TTM) | AU$1.59m |
Revenue (TTM) | AU$83.47m |
842.0x
P/E Ratio16.1x
P/S RatioIs PNV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PNV income statement (TTM) | |
---|---|
Revenue | AU$83.47m |
Cost of Revenue | AU$14.09m |
Gross Profit | AU$69.38m |
Other Expenses | AU$67.78m |
Earnings | AU$1.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.0023 |
Gross Margin | 83.12% |
Net Profit Margin | 1.91% |
Debt/Equity Ratio | 3.4% |
How did PNV perform over the long term?
See historical performance and comparison